Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Aruba Science Wire.
Press releases published on July 29, 2025

Flex Mobile Launches First-Ever Premium Membership Model in Prepaid Wireless
Los Angeles, CA, July 29, 2025 (GLOBE NEWSWIRE) -- Flex Mobile has officially launched its premium membership experience for prepaid wireless customers, introducing a first-of-its-kind customer rewards program that transforms a basic phone plan into a …

Treatment.com AI Engages Market Maker
Vancouver, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; 939: FRA) has engaged the services of Independent Trading Group ("ITG") pursuant to an agreement dated and starting …

Kneat to Announce 2025 Second-Quarter Financial Results August 5, 2025
LIMERICK, Ireland, July 29, 2025 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTC: KSIOF) (“Kneat” or the “Company”) a leader in digitizing and automating validation and quality processes, announced today that the Company will release its financial …

Rakovina Therapeutics Announces Stock Option Grants
VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug …

Axonius Acquires Medical Device Security Specialist Cynerio for More Than $100 Million to Target Healthcare Market
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Axonius, the global leader in cyber asset intelligence, today announced that it has acquired Cynerio, a pioneer in medical device security for more than $100 million in a cash and stock transaction. The …

Silvaco to Acquire Mixel, Inc. a Provider of Low-Power, High-Performance Mixed-Signal Connectivity IP Solutions
SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Silvaco Group, Inc. (“Silvaco”) (NASDAQ: SVCO), a provider of TCAD, EDA software, and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, today …

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage …

DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation
Châtillon, France, le 29 juillet 2025 DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique …

Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 …

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, …

DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025
Châtillon, France, le 29 juillet 2025 DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT-CUSIP : 23306J309), société biopharmaceutique …

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm – – Onvansertib …

Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference
REDWOOD CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Canaccord …

Varonis Announces Second Quarter 2025 Financial Results
Annual recurring revenues grew 19% year-over-year SaaS ARR as a percentage of total ARR was approximately 69% Year-to-date cash from operations generated $89.3 million vs. $68.4 million last year Year-to-date free cash flow generated $82.7 million vs. $67. …

Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The …

Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
- Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Announced …

EXL announces $125 million accelerated share repurchase program
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a global data and AI company, today announced that, as part of its capital allocation program, it has entered into an accelerated share repurchase agreement (the “ASR”) with Citibank, N.A. to …

Larimar Therapeutics Announces Proposed Underwritten Public Offering
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an …

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
- Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved Tolerability, …

EXL Reports 2025 Second Quarter Results
2025 Second Quarter Revenue of $514.5 Million, up 14.7% year-over-year Q2 Diluted EPS (GAAP) of $0.40, up 43.9% from $0.28 in Q2 of 2024 Q2 Adjusted Diluted EPS (Non-GAAP) (1) of $0.49, up 20.3% from $0.40 in Q2 of 2024 NEW YORK, July 29, 2025 (GLOBE …